Leaflet RYALTRIS 25mcg / 600mcg / dose nasal spray, solution


Indicated for: asthma; chronic obstructive pulmonary disease

Route of administration: nasal

Substance: olopatadine + mometasone (bronchodilator + glucocorticoid)

ATC: R01AD59 (Respiratory system | Decongestants and other nasal preparations for topical use | Corticosteroids)

The combination of olopatadine and mometasone is used in the treatment of seasonal or perennial allergic rhinitis. Olopatadine is an antihistamine that reduces allergic symptoms, while mometasone is a corticosteroid that reduces nasal inflammation.

The medication is administered as a nasal spray, as directed by a doctor, usually once or twice daily. It is important for patients to follow the recommended dosage and avoid long-term use without medical supervision.

Patients should be aware of potential side effects, such as nasal irritation, dryness, or nosebleeds. It is important to inform the doctor of any unusual symptoms.

Common side effects include nasal irritation, dryness, and nosebleeds. In rare cases, severe reactions such as nasal infections or allergic reactions may occur. Patients should be informed of these risks before use.

General data about RYALTRIS 25mcg / 600mcg / dose

  • Substance: olopatadine + mometasone
  • Date of last drug list: 01-05-2026
  • Commercial code: W67951003
  • Concentration: 25mcg / 600mcg / dose
  • Pharmaceutical form: nasal spray, solution
  • Quantity: 1
  • Product type: original
  • Price: 71.79 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: GLENMARK PHARMACEUTICALS S.R.O. - REPUBLICA CEHA
  • Holder: GLENMARK PHARMACEUTICALS S.R.O. - REPUBLICA CEHA
  • Number: 13994/2021/03
  • Shelf life: 3 years-after packaging for sale;after the first opening-2 months